Does Telenursing Improve Quality of Life in Breast Cancer Patients?
Nurse-led telenursing interventions for women diagnosed with breast cancer demonstrate a small to moderate pooled effect on quality of life, according to a systematic review and meta-analysis published in the September 2026 issue of Cancer Medicine (DOI: 10.1002/cam4.72098). Authored by Serena Ricchiuto and colleagues, the study evaluates remote support systems to address both the physical morbidity and emotional distress associated with the most commonly diagnosed malignancy in women.
- The meta-analysis evaluated 17 studies encompassing a total of 4,199 patients, comparing nurse-led telenursing against standard clinical care.
- Initial pooled results indicated a statistically significant improvement in quality of life (SMD = 0.40, p = 0.019), though adjustments for publication bias attenuated the effect size to non-significance.
- Exploratory subgroup analyses point toward higher efficacy in mobile application-based interventions compared to traditional telephone follow-ups.
Methodological Scope and Evaluation Framework of the Meta-Analysis
To gauge how remote digital nursing interventions mitigate these challenges, the research team conducted a systematic review following PRISMA 2020 guidelines and the Cochrane Handbook. Searches spanned five databases to identify randomized controlled trials and quasi-experimental studies assessing nurse-led telenursing.
Out of the 17 studies identified in the systematic review representing 4,199 participants, exactly seven provided sufficient quantitative data for inclusion in the meta-analysis. The primary outcome measured was overall quality of life. To ensure methodological rigor, the investigators deployed RoB 2.0 and ROBINS-I tools to assess the risk of bias across the literature, while the GRADE framework was utilized to rate the overall certainty of the evidence.
Evaluating Delivery Modes: Mobile Apps Versus Telephone Follow-Up
The analysis reveals distinct variations depending on the technological medium utilized. Initial unadjusted calculations yielded a standardized mean difference of 0.40 (95% CI [0.09, 0.70]; p = 0.019) in favor of telenursing. However, applying a trim-and-fill correction to account for potential publication bias adjusted the estimate to 0.14 (95% CI [-0.17, 0.45]), which did not reach statistical significance at p = 0.376.
Exploratory subgroup analyses demonstrated a more pronounced effect for mobile application-based platforms, yielding a standardized mean difference of 0.63 (95% CI [0.46, 0.80], I2 = 0%, k = 3). By contrast, traditional telephone follow-up protocols showed a smaller, highly heterogeneous pooled effect of 0.21 (95% CI [-0.34, 0.76], I2 = 85.2%, k = 4). The authors emphasize that these subgroup comparisons are strictly exploratory due to the small number of contributing studies.
Clinical Implications and Conflict of Interest Disclosures
The certainty of the evidence was graded as low, driven by methodological heterogeneity, wide confidence intervals, and the attenuation of the pooled effect following publication bias corrections. According to the published conflict of interest statement, the authors declared no competing financial interests or personal relationships that could have influenced the work.
Future clinical trials must incorporate high-quality, randomized designs with larger sample sizes to validate the efficacy of specific mobile health applications. As digital health continues to evolve within oncology, establishing clear regulatory benchmarks and standardized nursing protocols will determine whether telenursing can reliably transform long-term patient outcomes.